Первый опыт терапии рака пищевода с использованием иммунокорректора Трансфер фактор ТМ

Представлены первые наблюдения регрессии рака пищевода при приеме иммунокорректора Трансфер фактор™ в виде монотерапии и в составе комплексного лечения. Высказаны предложения по расширению использования препаратов Трансфер факторов в программах комплексного лечения рака пищевода и коррекции существующих подходов к ведению «инкурабельных» больных.

TRANSFER FACTOR AS A COMPONENT OF ESOPHAGEAL CANCER TREATMENT

Esophageal cancer refers to tumors with a poor prognosis. This is due to the anatomical localization of the tumor, its low sensitivity to radiotherapy and chemotherapy, and a high frequency of comorbidity. The existing situation requires the development of new effective treatments for cancer of the esophagus. One promising area is the immunotherapy of tumors with Transfer factor™ (TF). The authors describe two cases of treatment esophageal cancer using TF. In first case, a patient with cancer of the lower esophagus (T 1-2N 0M 0) due to severe comorbidities were refused special treatment. He was treated with transfer factor only. After two months of treatment was achieved complete tumor regression. It was confirmed by esophagoscopy. In the following 4 months was found local tumor progression without distant metastasis. Survival was 26 months from diagnosis. Another patient with cancer of the lower esophagus (T 1N 0M 0) had TF therapy on a background of teletherapy. After two months achieved complete tumor regression confirmed esophagoscopy. The patient is in stable remission at the moment. He is under the dynamic supervision by esophagoscopy. Conclusions about the pronounced therapeutic effect of TF in esophageal cancer, comparable with chemoradiotherapy. In this combination of immunotherapy by TF and radiotherapy has synergies and allows for complete regression of tumors of the esophagus. Suggested when the regression "incurable" cancer of the esophagus on the background of preparations TF back to the question about the possibility of special treatment. Also made proposals to expand these studies to obtain representative data on place and importance of of TF in the complex treatment of esophageal cancer.